Literature DB >> 17403377

Variability in response to antihypertensive drugs.

Barry J Materson1.   

Abstract

Heterogeneity of treatment effects (HTE) is a measure of the variations in individual treatment response to the same agent across a population. Hypertension affords an appropriate model for investigators of HTE. Use of blood pressure measurement guidelines and consistent techniques help to reduce the potential variability associated with clinician measurements. Patient characteristics such as age and race/ethnicity can affect blood pressure, including patient response and adverse events observed with antihypertensive medication. Through pharmacogenetic advances, potential underlying causes for such variation are emerging. The growing number of clinical examples of mutations that affect antihypertensive response includes multiple polymorphisms within the components of the renin-angiotensin-aldosterone system. The most prominent examples of these polymorphisms exist in the genes coding for angiotensinogen, angiotensin-converting enzyme, and the angiotensin II type 1 receptor. An understanding of the components of blood pressure variability and sources of HTE in antihypertensive therapy is important for analyzing published reports on this topic. It is also helpful when designing treatment protocols for individual patients with hypertension and in assessing their response to therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403377     DOI: 10.1016/j.amjmed.2007.02.003

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

1.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

2.  N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?

Authors:  Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

Review 3.  Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.

Authors:  Donna K Arnett; Steven A Claas
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

4.  The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.

Authors:  James L Pool; Robert Glazer; Nora Crikelair; Drew Levy
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 5.  Genomic variation and neurohormonal intervention in heart failure.

Authors:  Dennis M McNamara
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 6.  Population ancestry and genetic risk for diabetes and kidney, cardiovascular, and bone disease: modifiable environmental factors may produce the cures.

Authors:  Barry I Freedman; Jasmin Divers; Nicholette D Palmer
Journal:  Am J Kidney Dis       Date:  2013-07-26       Impact factor: 8.860

7.  Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups.

Authors:  Lauren Gooden; Lisa R Metsch; Margaret R Pereyra; C Kevin Malotte; Louise F Haynes; Antoine Douaihy; Jack Chally; Raul N Mandler; Daniel J Feaster
Journal:  AIDS Behav       Date:  2016-09

8.  Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.

Authors:  Mohamed H Shahin; Ana C Sá; Amy Webb; Yan Gong; Taimour Langaee; Caitrin W McDonough; Alberto Riva; Amber L Beitleshees; Arlene B Chapman; John G Gums; Stephen T Turner; Eric Boerwinkle; Steven E Scherer; Wolfgang Sadee; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Circ Cardiovasc Genet       Date:  2017-01

9.  Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.

Authors:  J D Duarte; S T Turner; B Tran; A B Chapman; K R Bailey; Y Gong; J G Gums; T Y Langaee; A L Beitelshees; R M Cooper-Dehoff; E Boerwinkle; J A Johnson
Journal:  Pharmacogenomics J       Date:  2012-02-21       Impact factor: 3.550

10.  A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.

Authors:  Mohamed H Shahin; Yan Gong; Caitrin W McDonough; Daniel M Rotroff; Amber L Beitelshees; Timothy J Garrett; John G Gums; Alison Motsinger-Reif; Arlene B Chapman; Stephen T Turner; Eric Boerwinkle; Reginald F Frye; Oliver Fiehn; Rhonda M Cooper-DeHoff; Rima Kaddurah-Daouk; Julie A Johnson
Journal:  Hypertension       Date:  2016-07-05       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.